Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kazuki Sugahara
Columbia University Health Sciences, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
DrugCendR, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sugahara owns equity in DrugCendR, LLC. The company is involved in drug development relating to technology being investigated in the this R01, and the company's efforts may benefit from the outcome of research under this grant. In light of these factors, Columbia has determined that the outcome of this research could affect the company and Dr. Sugahara's financial interest in DrugCendR, and that the design, conduct, and/or reporting of this research could be affected by Dr. Sugahara's interest in DrugCendR.
Note that DrugCendR is a new company, but the results of Columbia's FCOI review and the management plan being applied below track the review and management for Dr. Sugahara's prior company (no longer existing) called "CendR" that was the subject of a prior FCOI Report (#6826).
The role of fibroblasts in the activities of tissue penetrating peptides
Mechanistic studies to understand the exceptional tumor tissue and cell penetration of our iRGD peptide will be performed in view of carcinoma-associated fibroblast functions. Novel biological functions of iRGD that modify tumor microenvironment and lead to metastasis inhibition will also be explored. The project may result in a technology that enables targeting of clinically challenging desmoplastic cancers, and a comprehensive anti- cancer strategy that destroys existing tumors and inhibits metastasis simultaneously.
Filed on November 22, 2016.
Tell us what you know about Kazuki Sugahara's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Kazuki Sugahara filed other conflict of interest disclosures with the NIH:
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
Kazuki Sugahara | Columbia University Health Sciences | Conflict of Interest | CendR Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.